Novo Nordisk B A/S (NVO) on Wednesday announced the launch of the Wegovy pill in the United Arab Emirates, making it the first country outside the United States to offer the oral obesity treatment.
The company said Wegovy pill is the first oral GLP-1 receptor agonist approved for weight management.
The approval was based on results from the OASIS 4 trial, in which Wegovy taken once daily produced about 17% average weight loss in adults with obesity or overweight and at least one comorbidity. About one-third of participants achieved weight loss of 20% or more.
Novo Nordisk had previously said it planned to launch the Wegovy pill in selected markets in the second half of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.